Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
If approved it will bring a second source of MMR vaccine to the US market
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Nearly 6,000 patients have been treated with the drug since 2017
Deal signed with AOP Orphan for US commercial rights
The drug is indicated for mild and transient episodes of heart block
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Subscribe To Our Newsletter & Stay Updated
